|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
BUKWANG PHARMACEUTICAL CO.,LTD.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name BUKWANG PHARMACEUTICAL CO.,LTD. Headquarters 398-1, DAEBANG-DONG, DONGJAK-GU, SEOUL; Seoul; Seoul; 156811 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: Deloitte Touche Tohmatsu (2011) Incorporation Date: October 17, 1960 Total Employees: 536 Tel: 02-828-8114 |
|
Company Description |
| Preceding period level sales is maintained with slumping sales of products such as Parodontax due to severe competition despite growing sales of diabetic neuropath cure medicine.Net profit improved over the year-earlier period due to the active product sales.Stable financial structure is maintained with abundant liquidity while solid operating cash flow is maintained. Business growth will be slightly impeded by the market risk derived from government¡¯s constant ETC markdown policy while sales | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues decreased with -13.89%, from KRW 78,189,173 thousands to KRW 67,329,517 thousands. Operating result decreased from KRW 13,999,187 thousands to KRW 4,735,405 thousands which means -66.17% change. The results of the period decreased -67.17% reaching KRW 3,425,082 thousands at the end of the period against KRW 10,432,616 thousands last year. Return on equity (Net income/Total equity) went from 5.31% to 1.86%, the Return On Asset (Net income / Total Asset) went from 4.21% to 1.33% and the Net Profit Margin (Net Income/Net Sales) went from 13.34% to 5.09% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 39.40% compared to 26.18% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 3.69 to 7.89 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Y (non-cons) |
2012 H1 (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| KR listed company financials | KR listed company financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
247,919,262 |
256,808,131 |
| ||
Current Assets |
160,354,922 |
167,381,302 |
| ||
Total Liabilities |
51,686,407 |
72,582,691 |
| ||
Shareholders Equity |
196,232,855 |
184,225,440 |
| ||
Current Liabilities |
39,686,216 |
21,206,198 |
| ||
| * All the accounts are in KRW. | ||
Income Statement
| ||
Total Operating Revenue |
147,525,248 |
67,329,517 |
| ||
Operational Profit (Loss) |
21,440,383 |
4,735,405 |
| ||
Net Profit (Loss) |
16,511,915 |
3,425,082 |
| ||
| * All the accounts are in KRW. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
6.66% |
1.33% |
| ||
Return on Equity (ROE) |
8.41% |
1.86% |
| ||
Return on Sales (ROS) |
11.19% |
5.09% |
| ||
Return on Capital |
7.93% |
1.45% |
| ||
Gross Profit Margin |
53.95% |
50.86% |
| Efficiency Ratios | ||
| ||
Current asset turnover |
0.92x |
0.40x |
| ||
Asset Turnover |
0.60x |
0.26x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
7,774,533 |
433,820 |
| ||
EBITDA |
22,358,368 |
4,735,405 |
| ||
Bookvalue (BV) |
185,218,276 |
171,287,231 |
| Liquidity Ratios | ||
| ||
Current Ratio |
404.06% |
789.3% |
| ||
Quick ratio |
338.27% |
676.86% |
| ||
Doom's day ratio |
72.75% |
393.92% |
| ||
Cash Flow to Debt |
-64.53% |
29.36% |
| Leverage Ratios | ||
| ||
Leverage ratio |
126.34% |
139.4% |
| ||
Interest Coverage Ratio |
1,253.72% |
628.32% |
| ||
Debt to equity |
26.34% |
39.4% |
| ||
Debt to total assets |
20.85% |
28.26% |
| ||
Long Term Debt to Capital |
5.76% |
21.81% |
| Market ratios | ||
| ||
Price/Book Ratio |
2.03 |
1.68 |
| Trend Ratios | ||
| ||
Revenue Trend |
145.75% |
86.11% |
| ||
Net Income Trend |
257.75% |
32.83% |
| ||
 |